Insider Buying: Opko Health Inc. (OPK) CEO Acquires 200,000 Shares of Stock

Opko Health Inc. (NASDAQ:OPK) CEO Phillip Md Et Al Frost bought 200,000 shares of the company’s stock in a transaction that occurred on Monday, May 13th. The stock was purchased at an average price of $1.99 per share, with a total value of $398,000.00. Following the transaction, the chief executive officer now directly owns 3,068,951 shares in the company, valued at $6,107,212.49. The acquisition was disclosed in a filing with the SEC, which is available through the SEC website.

Phillip Md Et Al Frost also recently made the following trade(s):

  • On Friday, May 10th, Phillip Md Et Al Frost acquired 70,000 shares of Opko Health stock. The stock was bought at an average price of $2.08 per share, with a total value of $145,600.00.
  • On Wednesday, May 8th, Phillip Md Et Al Frost acquired 907,000 shares of Opko Health stock. The stock was bought at an average price of $2.11 per share, with a total value of $1,913,770.00.
  • On Monday, April 22nd, Phillip Md Et Al Frost acquired 80,000 shares of Opko Health stock. The stock was bought at an average price of $2.32 per share, with a total value of $185,600.00.
  • On Wednesday, April 17th, Phillip Md Et Al Frost purchased 50,000 shares of Opko Health stock. The stock was purchased at an average cost of $2.42 per share, for a total transaction of $121,000.00.
  • On Monday, April 15th, Phillip Md Et Al Frost purchased 10,000 shares of Opko Health stock. The stock was purchased at an average cost of $2.47 per share, for a total transaction of $24,700.00.
  • On Thursday, April 11th, Phillip Md Et Al Frost purchased 30,000 shares of Opko Health stock. The stock was purchased at an average cost of $2.49 per share, for a total transaction of $74,700.00.
  • On Tuesday, April 9th, Phillip Md Et Al Frost purchased 10,000 shares of Opko Health stock. The stock was purchased at an average cost of $2.51 per share, for a total transaction of $25,100.00.
  • On Thursday, April 4th, Phillip Md Et Al Frost purchased 20,000 shares of Opko Health stock. The stock was purchased at an average cost of $2.53 per share, for a total transaction of $50,600.00.
  • On Monday, April 1st, Phillip Md Et Al Frost purchased 20,000 shares of Opko Health stock. The stock was purchased at an average cost of $2.58 per share, for a total transaction of $51,600.00.
  • On Wednesday, March 27th, Phillip Md Et Al Frost purchased 100,000 shares of Opko Health stock. The stock was purchased at an average cost of $2.49 per share, for a total transaction of $249,000.00.

NASDAQ OPK opened at $2.01 on Thursday. Opko Health Inc. has a 12 month low of $1.92 and a 12 month high of $6.40. The firm has a market capitalization of $1.21 billion, a PE ratio of -8.04 and a beta of 1.81. The company has a debt-to-equity ratio of 0.13, a quick ratio of 0.99 and a current ratio of 1.10.



Opko Health (NASDAQ:OPK) last announced its quarterly earnings results on Tuesday, May 7th. The biotechnology company reported ($0.14) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.06) by ($0.08). The business had revenue of $222.50 million for the quarter, compared to the consensus estimate of $241.27 million. Opko Health had a negative net margin of 19.92% and a negative return on equity of 9.86%. The company’s revenue for the quarter was down 12.7% compared to the same quarter last year. During the same period in the previous year, the company earned ($0.08) earnings per share. As a group, equities analysts anticipate that Opko Health Inc. will post -0.42 earnings per share for the current year.

A number of research firms have recently commented on OPK. ValuEngine cut Opko Health from a “hold” rating to a “sell” rating in a research note on Wednesday, May 1st. Zacks Investment Research cut Opko Health from a “hold” rating to a “sell” rating in a research note on Friday, March 8th. Finally, Barrington Research reissued a “buy” rating and issued a $5.00 target price on shares of Opko Health in a research note on Thursday, February 28th. One equities research analyst has rated the stock with a sell rating and four have issued a buy rating to the company’s stock. The stock has a consensus rating of “Buy” and an average target price of $9.25.

Several large investors have recently made changes to their positions in the company. BlackRock Inc. lifted its holdings in shares of Opko Health by 1.4% during the fourth quarter. BlackRock Inc. now owns 30,276,662 shares of the biotechnology company’s stock valued at $91,133,000 after purchasing an additional 408,951 shares in the last quarter. Vanguard Group Inc lifted its holdings in shares of Opko Health by 2.1% during the third quarter. Vanguard Group Inc now owns 29,660,750 shares of the biotechnology company’s stock valued at $102,626,000 after purchasing an additional 614,442 shares in the last quarter. Vanguard Group Inc. lifted its holdings in shares of Opko Health by 2.1% during the third quarter. Vanguard Group Inc. now owns 29,660,750 shares of the biotechnology company’s stock valued at $102,626,000 after purchasing an additional 614,442 shares in the last quarter. Geode Capital Management LLC lifted its holdings in shares of Opko Health by 11.0% during the first quarter. Geode Capital Management LLC now owns 4,527,632 shares of the biotechnology company’s stock valued at $11,817,000 after purchasing an additional 449,235 shares in the last quarter. Finally, Dimensional Fund Advisors LP lifted its holdings in shares of Opko Health by 25.3% during the third quarter. Dimensional Fund Advisors LP now owns 4,440,784 shares of the biotechnology company’s stock valued at $15,363,000 after purchasing an additional 897,406 shares in the last quarter. 22.64% of the stock is currently owned by hedge funds and other institutional investors.

COPYRIGHT VIOLATION NOTICE: This piece was originally reported by Dakota Financial News and is the property of of Dakota Financial News. If you are reading this piece on another site, it was stolen and republished in violation of U.S. and international copyright & trademark laws. The original version of this piece can be read at https://dakotafinancialnews.com/2019/05/16/insider-buying-opko-health-inc-opk-ceo-acquires-200000-shares-of-stock.html.

About Opko Health

OPKO Health, Inc, a healthcare company, engages in the diagnostics and pharmaceuticals business in the United States, Ireland, Chile, Spain, Israel, Mexico, and internationally. The company's Diagnostics segment operates BioReference Laboratories, a clinical laboratory that offers laboratory testing services.

Further Reading: How is the LIBOR rate calculated?

Insider Buying and Selling by Quarter for Opko Health (NASDAQ:OPK)

Receive News & Ratings for Opko Health Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Opko Health and related companies with MarketBeat.com's FREE daily email newsletter.